Omega Therapeutics, trading on the OTC Markets under the symbol OMGAQ, is a biotechnology company specializing in the development of precision gene control therapeutics. Leveraging its proprietary OMEGA platform, the company focuses on the programmable regulation of endogenous gene expression to address a range of diseases with unmet medical needs. By targeting gene control elements with synthetic epigenetic controllers, Omega Therapeutics aims to achieve durable modulation of disease‐relevant genes without altering underlying DNA sequences.
The OMEGA platform employs a modular architecture of Engineered Chromatin Therapeutic (ECT) molecules designed to recognize specific genomic addresses and recruit epigenetic effectors. Through this approach, Omega Therapeutics can upregulate, downregulate or finely tune gene expression in a controlled manner. This precision allows for tailored therapeutic programs that seek to restore healthy gene function in conditions such as rare genetic disorders, immune‐mediated diseases and metabolic dysfunctions.
Omega Therapeutics has assembled a pipeline of preclinical and early clinical programs across diverse therapeutic areas. The company’s research efforts encompass inflammatory diseases, orphan indications and broader immunology targets. In addition to its internal research, Omega has pursued collaborations to expand the application of its OMEGA platform, partnering with leading academic institutions to advance its understanding of gene control mechanisms.
Headquartered in Cambridge, Massachusetts, Omega Therapeutics is led by a management team with deep expertise in epigenetics, synthetic biology and drug development. Under the leadership of President and Chief Executive Officer David L. Johnson, the company aims to translate its technological innovations into targeted therapies that offer novel treatment paradigms for patients worldwide.
AI Generated. May Contain Errors.
